Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    August 2020
  1. ZHANG H, Liang F, Yue J, Liu P, et al
    MicroRNA137 regulates hypoxiamediated migration and epithelialmesenchymal transition in prostate cancer by targeting LGR4 via the EGFR/ERK signaling pathway.
    Int J Oncol. 2020;57:540-549.
    PubMed     Abstract available


    April 2020
  2. XIA L, Bouamar H, Gu X, Zeballos C, et al
    Gli2 mediates the development of castrationresistant prostate cancer.
    Int J Oncol. 2020 Apr 13. doi: 10.3892/ijo.2020.5044.
    PubMed     Abstract available


  3. YU F, Lin Y, Xu X, Liu W, et al
    Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
    Int J Oncol. 2020 Apr 13. doi: 10.3892/ijo.2020.5043.
    PubMed     Abstract available


  4. ZHOU Y, Zhou Z, Ji Z, Yan W, et al
    Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10AS1/CBP/FOXM1 signaling pathway.
    Int J Oncol. 2020 Apr 1. doi: 10.3892/ijo.2020.5036.
    PubMed     Abstract available


  5. AMIRRAD F, Pytak PA, Sadeghiani-Pelar N, Nguyen JPT, et al
    Prostate field cancerization and exosomes: Association between CD9, early growth response 1 and fatty acid synthase.
    Int J Oncol. 2020;56:957-968.
    PubMed     Abstract available


    March 2020
  6. NAZIM UM, Yin H, Park SY
    Neferine treatment enhances the TRAILinduced apoptosis of human prostate cancer cells via autophagic flux and the JNK pathway.
    Int J Oncol. 2020 Mar 13. doi: 10.3892/ijo.2020.5012.
    PubMed     Abstract available


  7. CONTRERAS HR, Lopez-Moncada F, Castellon EA
    Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropinreleasing hormone receptors (Review).
    Int J Oncol. 2020 Mar 5. doi: 10.3892/ijo.2020.5008.
    PubMed     Abstract available


    February 2020
  8. WANG X, Fang Y, Sun W, Xu Z, et al
    Endocrinotherapy resistance of prostate and breast cancer: Importance of the NFkappaB pathway (Review).
    Int J Oncol. 2020 Feb 19. doi: 10.3892/ijo.2020.4990.
    PubMed     Abstract available


    December 2019
  9. LU Z, Wu C, Zhu M, Song W, et al
    Ophiopogonin D' induces RIPK1dependent necroptosis in androgendependent LNCaP prostate cancer cells.
    Int J Oncol. 2019 Dec 17. doi: 10.3892/ijo.2019.4945.
    PubMed     Abstract available


    October 2019
  10. LIN X, Kapoor A, Gu Y, Chow MJ, et al
    Assessment of biochemical recurrence of prostate cancer (Review).
    Int J Oncol. 2019 Oct 4. doi: 10.3892/ijo.2019.4893.
    PubMed     Abstract available


    July 2019
  11. LANG SH, Swift SL, White H, Misso K, et al
    A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
    Int J Oncol. 2019 Jul 16. doi: 10.3892/ijo.2019.4842.
    PubMed     Abstract available


  12. HAN Y, Liu C, Zhang D, Men H, et al
    Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle.
    Int J Oncol. 2019 Jul 15. doi: 10.3892/ijo.2019.4839.
    PubMed     Abstract available


    June 2019
  13. ZHANG P, Yang X, Wang L, Zhang D, et al
    Overexpressing miR335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer.
    Int J Oncol. 2019;54:1981-1994.
    PubMed     Abstract available


  14. PAN D, Jia Z, Li W, Dou Z, et al
    The targeting of MTDH by miR1455p or miR1453p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells.
    Int J Oncol. 2019;54:1955-1968.
    PubMed     Abstract available


  15. GAO Y, Li L, Li T, Ma L, et al
    Simvastatin delays castrationresistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin1.
    Int J Oncol. 2019;54:2054-2068.
    PubMed     Abstract available


    April 2019
  16. BOUAOUICHE S, Magadoux L, Dondaine L, Reveneau S, et al
    Glyceryl trinitrateinduced cytotoxicity of docetaxelresistant prostatic cancer cells is associated with differential regulation of clusterin.
    Int J Oncol. 2019;54:1446-1456.
    PubMed     Abstract available


    February 2019
  17. KURODA K, Liu H
    The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
    Int J Oncol. 2019 Feb 1. doi: 10.3892/ijo.2019.4706.
    PubMed     Abstract available


    December 2018
  18. HUANG ZG, He RQ, Mo ZN
    Prognostic value and potential function of splicing events in prostate adenocarcinoma.
    Int J Oncol. 2018;53:2473-2487.
    PubMed     Abstract available


    November 2018
  19. ZHENG XM, Zhang P, Liu MH, Chen P, et al
    MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.
    Int J Oncol. 2018 Nov 26. doi: 10.3892/ijo.2018.4647.
    PubMed     Abstract available


  20. NUNEZ-IGLESIAS MJ, Novio S, Garcia-Santiago C, Cartea ME, et al
    Effects of 3-butenyl isothiocyanate on phenotypically different prostate cancer cells.
    Int J Oncol. 2018;53:2213-2223.
    PubMed     Abstract available


  21. APOSTOLATOS AH, Ratnayake WS, Win-Piazza H, Apostolatos CA, et al
    Inhibition of atypical protein kinase Ciota effectively reduces the malignancy of prostate cancer cells by downregulating the NF-kappaB signaling cascade.
    Int J Oncol. 2018;53:1836-1846.
    PubMed     Abstract available


    September 2018
  22. WU K, Na K, Chen D, Wang Y, et al
    Effects of non-steroidal anti-inflammatory drug-activated gene-1 on Ganoderma lucidum polysaccharides-induced apoptosis of human prostate cancer PC-3 cells.
    Int J Oncol. 2018 Sep 28. doi: 10.3892/ijo.2018.4578.
    PubMed     Abstract available


  23. TAN Y, Wang L, Du Y, Liu X, et al
    Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Int J Oncol. 2018 Sep 27. doi: 10.3892/ijo.2018.4577.
    PubMed     Abstract available


    August 2018
  24. HAN G, Zhang X, Liu P, Yu Q, et al
    Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.
    Int J Oncol. 2018 Aug 16. doi: 10.3892/ijo.2018.4526.
    PubMed     Abstract available


    July 2018
  25. LIU P, Liang Y, Jiang L, Wang H, et al
    CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
    Int J Oncol. 2018 Jul 18. doi: 10.3892/ijo.2018.4487.
    PubMed     Abstract available


    June 2018
  26. LIU X, Sun Z, Li D, Deng J, et al
    Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer.
    Int J Oncol. 2018 Jun 29. doi: 10.3892/ijo.2018.4464.
    PubMed     Abstract available


    May 2018
  27. ZHANG J, Shao S, Han D, Xu Y, et al
    High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-kappaB signaling pathway.
    Int J Oncol. 2018 May 23. doi: 10.3892/ijo.2018.4420.
    PubMed     Abstract available


  28. OAK C, Khalifa AO, Isali I, Bhaskaran N, et al
    Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
    Int J Oncol. 2018 May 16. doi: 10.3892/ijo.2018.4407.
    PubMed     Abstract available


    April 2018
  29. QI Y, Zhao W, Li M, Shao M, et al
    High C-X-C motif chemokine 5 expression is associated with malignant phenotypes of prostate cancer cells via autocrine and paracrine pathways.
    Int J Oncol. 2018 Apr 30. doi: 10.3892/ijo.2018.4388.
    PubMed     Abstract available


  30. CHENG L, Zang J, Dai HJ, Li F, et al
    Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
    Int J Oncol. 2018 Apr 24. doi: 10.3892/ijo.2018.4377.
    PubMed     Abstract available


  31. LUO Y, Li M, Zuo X, Basourakos SP, et al
    betacatenin nuclear translocation induced by HIF1alpha overexpression leads to the radioresistance of prostate cancer.
    Int J Oncol. 2018 Apr 12. doi: 10.3892/ijo.2018.4368.
    PubMed     Abstract available


  32. DU Z, Li L, Sun W, Wang X, et al
    HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a gamma-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzaluta
    Int J Oncol. 2018 Apr 12. doi: 10.3892/ijo.2018.4370.
    PubMed     Abstract available


    November 2017
  33. CHEN S, Nimick M, Cridge AG, Hawkins BC, et al
    Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4207.
    PubMed     Abstract available


  34. EDWARDS DR, Moroz K, Zhang H, Mulholland D, et al
    PRL3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4208.
    PubMed     Abstract available


  35. XU W, Foster BA, Richards M, Bondioli KR, et al
    Characterization of prostate cancer cell progression in zebrafish xenograft model.
    Int J Oncol. 2017 Nov 6. doi: 10.3892/ijo.2017.4189.
    PubMed     Abstract available


    August 2017
  36. LU L, Li K, Mao YH, Qu H, et al
    Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
    Int J Oncol. 2017 Aug 10. doi: 10.3892/ijo.2017.4095.
    PubMed     Abstract available


    June 2017
  37. CHEN W, Liu Y, Chen H, Ning H, et al
    Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
    Int J Oncol. 2017 Jun 12. doi: 10.3892/ijo.2017.4038.
    PubMed     Abstract available


    May 2017
  38. BILIR B, Sharma NV, Lee J, Hammarstrom B, et al
    Effects of genistein supplementation on genomewide DNA methylation and gene expression in patients with localized prostate cancer.
    Int J Oncol. 2017 May 24. doi: 10.3892/ijo.2017.4017.
    PubMed     Abstract available


  39. OKATO A, Arai T, Kojima S, Koshizuka K, et al
    Dual strands of pre-miR150 (miR1505p and miR1503p) act as antitumor miRNAs targeting SPOCK1 in naive and castration-resistant prostate cancer.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4008.
    PubMed     Abstract available


    April 2017
  40. LU S, Dong Z
    Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
    Int J Oncol. 2017 Apr 19. doi: 10.3892/ijo.2017.3964.
    PubMed     Abstract available


    March 2017
  41. QIAN B, Yao Y, Liu C, Zhang J, et al
    SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
    Int J Oncol. 2017 Mar 22. doi: 10.3892/ijo.2017.3926.
    PubMed     Abstract available


    December 2016
  42. HARTING T, Stubbendorff M, Willenbrock S, Wagner S, et al
    The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro.
    Int J Oncol. 2016;49:2341-2350.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: